New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
08:49 EDTGSK, THRXGSK, Theravance announce Phase III study of FF/VI in Japan
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid, or ICS, fluticasone furoate and long-acting beta2 agonist, or LABA, vilanterol, or FF/VI. The study will evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease, or COPD. Positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan. The study is a 12 week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once daily compared with VI 25mcg once daily, administered via the Ellipta inhaler. Patients included in the study will have a history of COPD with at least one exacerbation in the year prior to screening and will demonstrate current symptoms of COPD. The study seeks to enrol approximately 1580 patients from across 250 study centres worldwide, including approximately 350 patients from centres in Japan.
News For GSK;THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 6, 2015
07:29 EDTGSKGlaxoSmithKline sees core EPS to grow mid-to-high single digit CAGR in 2016-2020
Subscribe for More Information
07:28 EDTGSKGlaxoSmithKline reports Q1 adjusted EPS 17.3p, consensus 17.4p
Reports Q1 core sales of GBP5.6B, consensus GBP5.65B.
05:48 EDTGSKViiV Healthcare begins Phase III trial with dolutegravir/rilpivirine combination
Subscribe for More Information
May 5, 2015
15:02 EDTGSKNotable companies reporting before tomorrow's open
Subscribe for More Information
09:31 EDTGSKGlaxoSmithKline, partners make EU submission for gene therapy to treat ADA-SCID
Subscribe for More Information
May 3, 2015
18:11 EDTGSKSiemens investigated by Chinese regulator last year, Reuters says
Subscribe for More Information
May 1, 2015
07:43 EDTGSKExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
16:59 EDTTHRX, GSKGlaxoSmithKline, Theravance announce FDA approval of Breo Ellipta
Subscribe for More Information
15:20 EDTGSK, THRXGlaxo says FDA issued CRL on use of Breo Ellipta in patients aged 12-17
Subscribe for More Information
15:17 EDTTHRX, GSKGlaxoSmithKline says FDA approves BREO ELLIPTA for adults with asthma
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the FDA has approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. Breo is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
11:06 EDTTHRXOptions with increasing implied volatility
Subscribe for More Information
07:21 EDTTHRX, GSKFDA PDUFA Date for Theravance BREO ELLIPTA is April 30, 2015
April 29, 2015
10:53 EDTTHRXOptions with increasing implied volatility
Options with increasing implied volatility: THRX ALTR ARIA DECK ANF KORS CVC CCE
April 28, 2015
11:04 EDTTHRXOptions with increasing implied volatility
Subscribe for More Information
April 27, 2015
12:28 EDTTHRXOptions with increasing implied volatility
Options with increasing implied volatility: THRX ARRY AKRX DECK HSBC
10:04 EDTGSKHigh option volume stocks
Subscribe for More Information
08:46 EDTGSKAgenus data positive, says JMP Securities
Subscribe for More Information
08:41 EDTGSKTelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTGSKPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
07:11 EDTGSKAgenus: GSK's RTS,S vaccine showed statistically significant results in study
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use